33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Idecabtagene vicleucel (Ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 a phase 3 randomized controlled trial (RCT)
    Meeting Abstract

    Scheid, C.; Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Alternative schedule of temozolomide/capecitabine (TEMCAP) administration in patients with neuroendocrine neoplasms
    Meeting Abstract

    Melhorn, P.; Mazal, P.; Wolff, L.; Popov, P.; Kretschmer-Chott, E.; Haug, A.; Mayerhoefer, M. E.; Raderer, M.; Kiesewetter, B.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Risk profiling of patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): 3-year update of the POLARIX study
    Meeting Abstract

    Oellerich, T.; Lenz, G.; Herrera, A. F.; McCord, R.; Kimes, P.; Jardin, F.; Trnény, M.; Flowers, C. R.; Sehn, L. H.; Salles, G.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Neopeptide diversity and similarity to the unmutated immunopeptidome is associated with response to immune checkpoint blockade therapy
    Meeting Abstract

    Klatt, M.; Molvi, Z.; Panageas, K.; Wells, D.; Hellmann, M.; Merghoub, T.; Wolchok, J.; O'Reilly, R.; Keller, U.; Scheinberg, D.
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Meeting Abstract

    Rieke, D. T.; Lin, J. I.; Tan, D. S.; Kummar, S.; Patel, J. D.; Cermignani, L.; Dai, M. S.; Lassen, U. N.; Leyvraz, S.; Liu, Y.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Meeting Abstract

    Goetze, T.; Melisi, D.; Macarulla, T.; Cid, R. A. P.; Chandana, S. R.; De La Fouchardière, C.; Dean, A.; Kiss, I.; Lee, W. J.; Van Cutsem, E.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • B cells control autoimmunity against AQP4 by negative selection of antigen-specific thymocytes
    Meeting Abstract

    Afzali, A.; Nirschl, L.; Sie, C.; Pfaller, M.; Oleksii, U.; Hassler, T.; Federle, C.; Petrozziello, E.; Kalluri, S. R.; Chen, H. H.; more...
    Multiple Sclerosis Journal (2023)

    Fulltext@MSK | Save
  • National impact of the COVID-19 pandemic on the diagnosis and management of esophagogastric cancer: A national cancer database study
    Meeting Abstract

    Abate, M. E.; Schleimer, L. E.; Toumbacaris, N.; Fei, T.; Strong, V. E.; Molena, D.
    Journal of the American College of Surgeons (2023)

    Fulltext@MSK | Save
  • A comparison of risk factors for isolated vs secondary delayed gastric emptying after pancreatoduodenectomy
    Meeting Abstract

    Valukas, C. S.; Logan, C.; Ellis, R. J.; Merkow, R. P.; Bentrem, D. J.
    Journal of the American College of Surgeons (2023)

    Fulltext@MSK | Save
  • Echocardiographic analysis of AngioVac treatment for infective endocarditis: A single-center experience
    Meeting Abstract

    Saleem, D.; Onkaramurthy, N. J.; Alsaloum, M.; Min, S.; Burton, J.; Snyder, D.; Madhavan, M.; Lebehn, M.; Kampaktsis, P.; Kodali, K.; more...
    Journal of the American College of Cardiology (2023)

    Fulltext@MSK | Save